Aikaterini Detoraki - Publications

Dupilumab-Related Hypereosinophilia in Patients Treated for Type 2 Diseases: Evidence from a 24-Month Prospective Real-Life Study.

Journal: Journal of clinical medicine

Published: January 21, 2026

Effectiveness and Safety of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps and Associated T2 Comorbidities: One-Year Real Life Round.

Journal: Journal of clinical medicine

Published: December 10, 2025

The Overlooked Burden of Atopic Comorbidities in Eosinophilic Esophagitis: Insights from a Real-Life Comprehensive Multidisciplinary Evaluation.

Journal: Journal of clinical medicine

Published: September 12, 2025

Short-term effectiveness of tezepelumab on ENT manifestations in patients undergoing treatment for severe asthma: A pilot real-life study.

Journal: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Published: July 29, 2025

Clinical and immunological biomarkers in hypereosinophilic syndrome: the second step after diagnostic algorithms.

Journal: Frontiers in medicine

Published: March 26, 2025

Optimising care for chronic rhinosinusitis with nasal polyps and asthma in multimorbid patients: a multidisciplinary Delphi consensus.

Journal: Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale

Published: January 14, 2025

The Potential Role of Nasal Cytology in Respiratory Diseases: Clinical Research and Future Perspectives.

Journal: Journal of clinical medicine

Published: December 19, 2024

The Effects of Mepolizumab on CRSwNP: Real-Life Evidence.

Journal: Journal of personalized medicine

Published: September 19, 2024

Managing Patients with Hypereosinophilic Syndrome: A Statement from the Italian Society of Allergy, Asthma, and Clinical Immunology (SIAAIC).

Journal: Cells

Published: April 11, 2024

Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis.

Journal: Respirology (Carlton, Vic.)

Published: January 10, 2024

Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission.

Journal: Frontiers in immunology

Published: November 23, 2023

Early Ear, Nose and Throat Manifestations in Eosinophilic Granulomatosis with Poliangioitis: Results from Our Cohort Group and Literature Review.

Journal: Journal of clinical medicine

Published: September 14, 2023